Zealand Pharma A/S (OTCMKTS:ZLDPF) Issues Earnings Results, Beats Estimates By $0.53 EPS

Zealand Pharma A/S (OTCMKTS:ZLDPF) released its earnings results on Thursday. The company reported ($0.81) earnings per share for the quarter, beating the consensus estimate of ($1.34) by $0.53, Zacks reports. Zealand Pharma A/S had a return on equity of 55.76% and a net margin of 71.79%.The company had revenue of $10.79 million for the quarter, compared to the consensus estimate of $19.69 million.

Zealand Pharma A/S Trading Down 2.7%

Zealand Pharma A/S stock opened at $60.42 on Friday. Zealand Pharma A/S has a 52 week low of $49.98 and a 52 week high of $101.29. The company has a debt-to-equity ratio of 0.02, a quick ratio of 14.10 and a current ratio of 14.10. The business’s 50-day simple moving average is $68.66 and its 200-day simple moving average is $70.39. The firm has a market capitalization of $4.29 billion, a PE ratio of 4.35 and a beta of 0.72.

Wall Street Analysts Forecast Growth

A number of research analysts recently issued reports on ZLDPF shares. Deutsche Bank Aktiengesellschaft restated a “hold” rating on shares of Zealand Pharma A/S in a research report on Tuesday, December 16th. BTIG Research upgraded shares of Zealand Pharma A/S to a “strong-buy” rating in a research note on Friday, November 28th. Five research analysts have rated the stock with a Strong Buy rating and two have assigned a Hold rating to the stock. According to data from MarketBeat, Zealand Pharma A/S has an average rating of “Buy”.

Zealand Pharma A/S Company Profile

Zealand Pharma A/S is a Denmark‐based biopharmaceutical company specializing in the discovery, design and development of peptide‐based therapeutics. Utilizing proprietary peptide engineering platforms, the company focuses on metabolic and endocrine disorders, including diabetes and rare gastrointestinal diseases. Zealand employs a rational design approach to optimize stability, selectivity and dosing profiles of its candidates, aiming to improve patient outcomes where current treatment options are limited.

Among the most advanced assets in Zealand’s pipeline is dasiglucagon, a stable glucagon analog designed for the emergency treatment of severe hypoglycemia.